Pompe Disease Drug-Specific Eligibility & Continuation Criteria

Effective 03/01/2026 Blue Cross Blue Shield of Louisiana consolidated and clarified agent-specific initial and continuation criteria for enzyme replacement and adjunctive therapies for Pompe disease (Policy #00771). The update lists distinct eligibility, baseline testing (percent predicted FVC and 6MWT), age/weight limits, and objective response thresholds for alglucosidase alfa (Lumizyme), avalglucosidase alfa-ngpt (Nexviazyme), cipaglucosidase alfa-atga (Pombiliti), and miglustat (Opfolda), and prohibits certain concurrent combinations. Continuation requires documented stabilization or improvement versus pretreatment baselines with numeric ambulation/FVC/ventilation limits; several criteria are explicitly labeled as Company requirements and will be denied if unmet. Diagnostic confirmation by GAA enzyme assay or genetic testing and trial context for infantile-onset disease are reiterated to support coverage decisions.

This revision (Current Effective Date: 03/01/2026) clarifies and consolidates drug-specific eligibility and continuation criteria for enzyme replacement and adjunctive therapy for Pompe disease under Policy # 00771 for Blue Cross Blue Shield - Louisiana. The document explicitly enumerates distinct initial and continuation requirements for alglucosidase alfa (Lumizyme), avalglucosidase alfa-ngpt (Nexviazyme), cipaglucosidase alfa-atga (Pombiliti), and miglustat (Opfolda), and restates historical trial inclusion/context (Trial 1) for infantile-onset disease.

Key additions include explicit prohibitions on concurrent combination use of certain agents (e.g., use of Lumizyme or Pombiliti with Opfolda) when requesting another listed agent, and repeated emphasis that several criteria are "additional Company requirements" and will be denied as not medically necessary if not met. The revision also standardizes baseline assessment expectations (percent predicted FVC and 6MWT) across several agents and clarifies age and weight thresholds for Pombiliti and Opfolda initial authorization.

The policy defines distinct initial authorization criteria for each therapy. For alglucosidase alfa (Lumizyme), initial approval requires documented GAA enzyme deficiency (any tissue source) and/or two confirmed GAA gene mutations plus measurable signs of Pompe disease (examples listed include cardiac hypertrophy, pulmonary impairment, or motor weakness). For late-onset patients initiating Lumizyme, additional requirements include ambulation ≥ 130 feet, sitting FVC ≥ 30% and < 80% predicted, and no use of invasive or awake noninvasive ventilation.

For avalglucosidase alfa-ngpt (Nexviazyme), the policy adds trial-based exclusions: the patient must not require invasive ventilation, must not have Pompe-specific cardiac hypertrophy, and baseline FVC and 6MWT must be provided. For cipaglucosidase alfa-atga (Pombiliti) and miglustat (Opfolda), initial authorization requires late-onset Pompe diagnosis (enzyme assay < 40% lab mean or genetic testing), age ≥ 18 years, weight ≥ 40 kg, measurable disease signs (including cardiac hypertrophy among listed signs), and a requirement that the patient has NOT demonstrated improvement after ≥ 1 year of prior Lumizyme or Nexviazyme unless contraindicated or expected to be ineffective.

Continuation/renewal criteria are specified per agent and tied to objective measures. For Lumizyme, continuation requires prior initial authorization and demonstration of benefit compared to pretreatment baseline in at least one domain; infants: stabilization or improvement in muscle weakness, motor function, respiratory function, cardiac involvement, FVC and/or 6MWT; late-onset: stabilization or improvement in FVC and/or 6MWT. Additional late-onset numeric thresholds (ambulation ≥ 130 feet, FVC ≥ 30% and < 80%, no invasive/awake noninvasive ventilation) are reiterated for continuation.

For Nexviazyme, continuation requires improvement or stabilization in percent predicted FVC and/or 6MWT, adherence to dosing guidance (≥ 30 kg: 20 mg/kg q2w; < 30 kg: 40 mg/kg q2w), ambulation ≥ 130 feet without assistive device, FVC ≥ 30% and ≤ 85% predicted, no invasive ventilation, and absence of Pompe-specific cardiac hypertrophy. For Pombiliti and Opfolda, continuation similarly requires objective improvement or stabilization in FVC and/or 6MWT and limits on ventilation support (not requiring > 6 hours/day while awake).

The policy explicitly identifies situations considered not medically necessary across agents. For Lumizyme, use is considered not medically necessary if the patient lacks measurable signs of Pompe disease (cardiac hypertrophy, pulmonary impairment, or motor weakness). For Nexviazyme, the policy lists multiple not-medically-necessary conditions: absence of measurable signs (pulmonary impairment or motor weakness), inability to ambulate ≥ 130 feet without stopping, FVC < 30% or > 85% predicted, requirement for invasive ventilation, presence of Pompe-specific cardiac hypertrophy, or missing baseline FVC/6MWT data. For Pombiliti and Opfolda, use is considered not medically necessary if the patient lacks measurable disease signs, has not failed or not improved on prior Lumizyme or Nexviazyme for ≥ 1 year (unless contraindicated), has a 6MWD ≥ 75 meters, sitting FVC < 30% predicted, or requires invasive/noninvasive ventilation > 6 hours/day while awake.

These not-medically-necessary statements are repeated and labelled as Company requirements, indicating strict adherence to the documented thresholds and objective testing (e.g., FVC, 6MWT) as gatekeepers for coverage.

The policy includes diagnostic and clinical context that anchors eligibility to confirmatory testing and common clinical presentations. Diagnosis of Pompe disease must be established by decreased acid alpha-glucosidase activity in blood, fibroblasts, or muscle tissue, or by GAA genetic testing, consistent across agents. The document reiterates the disease distinction between infantile-onset (IOPD) and late-onset (LOPD) forms, noting IOPD’s association with early cardiopulmonary failure and cardiac hypertrophy, and LOPD’s typical presentation with progressive skeletal myopathy and respiratory failure without cardiomyopathy.

Trial 1 (IOPD) is summarized in the policy to provide evidence context for Lumizyme: an open-label trial enrolling infants ≤ 7 months with cardiac hypertrophy and no ventilatory support at entry, showing improved ventilator-free survival compared with historical controls and decreases in left ventricular mass index (LVMI) at 12 months, although LVMI change did not correlate with ventilator-free survival. This clinical context supports the policy’s emphasis on measurable signs such as cardiac hypertrophy and specific functional endpoints (FVC, 6MWT) as part of coverage determinations.

OpenPayer

March 2026 Revision: Consolidated, Drug-Specific Eligibility and Continuation Criteria

Initial Authorization: Distinct Entry Criteria for Each Agent

Continuation and Objective Response Requirements (FVC/6MWT/Functional Measures)

Enumerated Denial Criteria: When Use Is Considered Not Medically Necessary

Diagnostic Confirmation and Clinical Trial Context Linking Cardiac Hypertrophy to Coverage